Xilio Therapeutics Overview
- Founded
-
2016
- Status
-
Public
- Employees
-
78
- Stock Symbol
-
XLO
- Share Price
-
$2.47
- (As of Wednesday Closing)
Xilio Therapeutics General Information
Description
Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index.
Contact Information
Website
www.xiliotx.com
Formerly Known As
Akrevia Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Stock Exchange
NAS
Primary Office
- 828 Winter Street
- Suite 300
- Waltham, MA 02451
- United States
+1 (617) 000-0000
Xilio Therapeutics Timeline
Xilio Therapeutics Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.47 | $2.42 | $2.04 - $27.95 | $66.5M | 27.5M | 116K | -$3.24 |
Xilio Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 16,688 | 583,293 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (78,697) | (74,301) | (54,154) | (17,071) |
| Net Income | (80,486) | (75,800) | (55,219) | (17,311) |
| Total Assets | 196,352 | 218,060 | 36,317 | 62,722 |
| Total Debt | 20,402 | 20,536 | 21,217 | 18,631 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Xilio Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Xilio Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Xilio Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable cl
Drug Discovery
Waltham, MA
78
As of 2022
00000
0000
0000-00-00
00000000
00000
000000
do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000 000000000
Cambridge, MA
00
As of 0000
00000
0000
0000-00-00
00000000
00000
Add Comparison
Xilio Therapeutics Competitors (1)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 00000000 000000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
Xilio Therapeutics Executive Team (15)
Xilio Therapeutics Board Members (25)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christina Rossi | Self | Board Member | 000 0000 |
| Daniel Curran | Takeda Ventures | Board Member | 000 0000 |
| Daniel Lynch | Self | Chairman of the Board | 000 0000 |
| Michael Ross Ph.D | SV Health Investors | Board Member | 000 0000 |
| Paul Clancy | Self | Chairman & Board Member | 000 0000 |
Xilio Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Xilio Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|